RxDoctor Payments DataLook up a doctor →

Jonathan Grainger, MD

Pain Medicine · Florence, KYNPI 1861718157

Payments from drug & device makers

$21,998in general payments, 2019–2025

Across 600 payments — averaging $36.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • Medtronic$6K
  • Abbott$5K
  • Relievant Medsystems, Inc.$1K
  • AbbVie$1K
  • Vertos Medical, Inc.$657
  • plus $2K from 30 others

What the payments were for

  • Travel & lodging$4,34020%
  • Food & beverage$17,65880%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,998 in reported general payments places this provider in the 85th percentile of 90 pain medicine providers in Kentucky.

See all pain medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$111,528
Medicare patients
348
Services billed
5,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl66$58,778
Xtampza ErOxycodone Myristate65$48,081
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,500$42,853
Buprenorphine113$32,188
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,021$20,608
NucyntaTapentadol Hcl12$16,991
Oxycodone Hcl876$16,946
OxycontinOxycodone Hcl16$6,495
Morphine Sulfate ErMorphine Sulfate162$5,073
Fentanyl31$2,359
Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine15$2,277
Pregabalin64$2,018
Gabapentin193$1,987
Meloxicam23$1,041
Naloxone Hcl18$1,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta$477$123,850143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 90 pain medicine providers in Kentucky.

Other pain medicine in Florence

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →